Human ASNS Stable Cell Line - Hep G2

The ASNS gene encodes asparagine synthase, an enzyme that plays a crucial role in cellular nitrogen homeostasis. It catalyzes the synthesis of L-asparagine from L-aspartate and L-glutamine in an ATP-dependent reaction. This enzymatic activity is essential for protein biosynthesis, especially during periods of nutritional stress when exogenous asparagine supply is insufficient. ASNS transcription is tightly regulated by the integrated stress response (ISR), particularly through the binding of the transcription factor ATF4 to the amino acid response element (AARE) in its promoter region. Clinically, ASNS is a key factor in the treatment of acute lymphoblastic leukemia (ALL). Tumor cells in ALL are typically deficient in ASNS and dependent on blood-derived asparagine, and L-asparaginase therapy targets this deficiency. However, upregulation of ASNS is a major mechanism by which resistance to these therapies develops. In solid tumors such as breast and pancreatic cancer, asparagine synthase (ASNS) levels are typically elevated and associated with increased metastatic potential and poor prognosis because asparagine is an exchange factor for other essential amino acids. Furthermore, homozygous or compound heterozygous mutations in the ASNS gene lead to asparaginase deficiency (ASD), a severe congenital neurological disorder characterized by microcephaly, refractory epilepsy, and global developmental delay.

The stable human ASNS cell line in the Hep G2 context provides a robust and physiologically relevant model for studying the molecular mechanisms of hepatic amino acid metabolism and stress responses. Derived from human hepatocellular carcinoma, Hep G2 cells retain many characteristics of primary hepatocytes, making them a gold standard platform for studying metabolic flux and drug toxicity. By stably overexpressing human ASNS, this cell line allows researchers to investigate how enhanced asparaginase production affects metabolic reprogramming of hepatocellular carcinoma cells and their survival under amino acid deficiency or chemotherapy stress. This product has wide applications in the pharmaceutical industry for high-throughput screening of ASNS inhibitors, which are being developed as potential anticancer drugs for combination therapy to overcome asparaginase resistance. In addition, the ASNS-Hep G2 model is an important tool for studying the "metabolic crosstalk" between ISR and lipid metabolism in the context of non-alcoholic fatty liver disease (NAFLD).